Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2006-06-20
2006-06-20
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S078040, C424S451000, C424S464000
Reexamination Certificate
active
07063857
ABSTRACT:
The present invention provides an agent for treating a dry eye, which contains a macrolide compound such as FK506.
REFERENCES:
patent: 5457182 (1995-10-01), Wiederrecht et al.
patent: 5770607 (1998-06-01), Honbo et al.
patent: 5932243 (1999-08-01), Fricker et al.
patent: 5952371 (1999-09-01), Baker et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6376517 (2002-04-01), Ross et al.
patent: 6489335 (2002-12-01), Peyman
patent: 0 184 162 (1986-06-01), None
patent: 0 240 773 (1987-10-01), None
patent: 0 323 042 (1989-07-01), None
patent: 0 406 791 (1991-01-01), None
patent: 0 423 714 (1991-04-01), None
patent: 0 427 680 (1991-05-01), None
patent: 0 465 426 (1992-01-01), None
patent: 0 480 523 (1992-04-01), None
patent: 0 532 088 (1993-03-01), None
patent: 0 532 089 (1993-03-01), None
patent: 0 532 862 (1993-03-01), None
patent: 0 569 337 (1993-11-01), None
patent: 0 626 385 (1994-11-01), None
patent: 2 278 780 (1994-12-01), None
patent: WO 89/05303 (1989-06-01), None
patent: WO 91/13889 (1991-09-01), None
patent: WO 91/19495 (1991-12-01), None
patent: WO 93/05058 (1993-03-01), None
patent: WO 93/05059 (1993-03-01), None
patent: WO 94/09010 (1994-04-01), None
patent: WO 95/16691 (1995-06-01), None
patent: 96 31514 (1996-10-01), None
patent: WO 96/31514 (1996-10-01), None
patent: 97 25977 (1997-07-01), None
patent: WO 98/36747 (1998-08-01), None
patent: 99 55332 (1999-11-01), None
patent: 00 09109 (2000-02-01), None
Web MD health Guide, “Keratoconjunctivitis, Vernal”, pp. 1-3, NIH/National Eye Institute, Mar. 18, 2003.
Yamada, M., et al.,Folia Ophthalmol. Jpn., vol. 43, pp. 1289-1293 (1992).
Jihong Yang et al.: “Sjogren's syndrome in mice carrying the Iprcg gene and the therapeutic efficacy of an immunasuppressive agent FK506” Pathol. Int., pp. 133-140 Feb. 1999.
K. Tsubota: “New approaches to dry-eye therapy” International Ophthalmology Clinics, US, Little, Brown, Boston, vol. 34, No. 1, pp. 115-128 1994.
H. Iwamoto et al.: “Inhibitory effects of FK506 on development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration.” Graefes Archive for Clinical and Experimental Ophthalmology, pp. 407-417 May 1999.
A. Tsujikawa et al.: “Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia” Stroke, US, American Heart Association, Dallas TX, vol. 29, No. 7, pp. 1431-1438 1998.
K.F. Tabbara et al.: “Dry eye syndrome” Drugs of Today/Medicamentos De Actualidad, ES, J.R. Prous SS.A International Publishers, vol. 34, No. 5, pp. 447-453 1998.
Azpuru Carlos A.
Sucampo AG
LandOfFree
Use of macrolide compounds for the treatment of dry eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of macrolide compounds for the treatment of dry eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of macrolide compounds for the treatment of dry eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3690457